FilingSEC EDGAR6-K
Radiopharm Theranostics Secures $8M Advance on FY26 R&D Tax Incentive
· SEC accepted
StageClinical stage
Filing content
The company has secured $8 million in funding secured against its anticipated FY26 R&D tax incentive to support clinical trials and working capital.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…